Differences in the rate of introduction of LPAIv could be used to (re)design a targeted risk-based surveillance programme.
No takes yet. Share an insight, caveat, or question.
Gonzáles et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: